

Index

- 5-HT transporter (5-HTT), 21
- addiction, *see also* substance use disorders
 application to genetic research on, 98–9
 as brain disease, 5, 224–7
 conceptions of, 3–7, 232–3
 criteria for, 2–3
 epigenetic mechanisms and, 218
 ethical issues in
 human genetic research, 9–10
 translating and applying genetic research, 10–11
 genetic research related to, *see* genetic research, on addiction
 genetic susceptibility to, 147
 human behaviors for, 215–21
 individualization and
 internalization of, 224–7
 moral model of, 4, 7
 pharmacogenetic testing for, 157–9
 social impacts of medicalization of
 addiction treatment, 167
 research and public policy priorities, 166–7
 stigma and discrimination, 165–6
 stigma, associated with, 181–5
 symptoms of, 232
 testing of individuals for alleles associated with, 234
 “addiction-free” smokers, 144
 addictive consumptions, profits from
 continuum of risks associated with, 131–2
 difference with ordinary consumptions, 124–5
 moral jeopardy involving, 125
 contributory risks, 126–7
 democratic risks, 130–1
 ethical risks, 125–6
 governance risks, 128–9
 relationship risks, 129–30
 reputational risks, 127–8
- network of beneficiaries, 124
 position of research groups
 regarding, 132
 product design research, funded by tobacco industry, 134–5
 public health research, on youth alcohol consumption, 132–3
 university chair, in gambling studies, 133–4
- addictive disorders,
 pharmacogenetic testing for treatment of, 8
- adolescents, with drug addictions, 111
- aerodigestive cancers, 158
- Alcohol Consumption Scale, 200
- alcohol consumption, deaths caused by, 125
- alcohol dehydrogenase (ADH), 18, 19
- alcohol dependence (AD), 16
 applications of genomic medicine for
 personalized treatment, 24–5
 preventive and predictive screening, 23–4
 candidate genes for, 17–18
 challenges in establishing genetic basis for, 21–3
 clinical studies of, 31
 disease concept of, 196
 genetic explanations for stability and uncontrollability of, 197, 202, 204
 genetic factors influencing, 196–7, 201
 genetic variants involved in development and persistence of, 16
 health fatalism, role of, 206–7
 limitations and future research on, 207
 medical model of, 196
 methods for analyzing development of
 measures, 198–201
 sample, 198
- naltrexone therapy for, 155, 157, 163
 perceived risk for developing, 198, 202, 204–5
 population screening for, 233
 prevalence of genetic explanations for, 203–4
 public beliefs in genetic causes of, 185
 risk of, 19
 susceptibility alleles for, 17
 treatments of, 16
- alcohol metabolism, genes that impact on, 18–19
- alcohol prevention, implications for, 208
- alcohol use disorders, 16
- Alcohol: No Ordinary Commodity* (2010), 124
- Alcoholic Beverage Medical Research Foundation (ABMRF), 141, 143, 166
- Alcoholics Anonymous, 184
- alcoholism, *see* alcohol dependence (AD)
- alcohol-related birth defects, 18
- aldehyde dehydrogenase (ALDH), 18
- Alzheimer's disease, 38, 115, 182
- American eugenics movement, 10
- American Gaming Association (AGA), 143, 224
- American Medical Association, 196
- American Psychiatric Association, 3, 6
- American Recovery and Reinvestment Act (2009), 86, 93
- Americans with Disabilities Act (ADA), 88
- Asp40* allele, of the *OPRM1* gene, 167
- Association for Molecular Pathology et al. v. U.S. Patent and Trademark Office* (2010), 118

- attribution theory, for stigma reduction, 185–6
 outcomes related to, 188
 audio-visual technologies, use of, 47–8
- Babor, Thomas, 124
 behavioral genetics, limitations of, 233
Belmont Report, The, 42, 43, 44, 62
 Bermuda Rules, for sharing of samples and data for genomic databases, 111
 biobanks, 10, 12, 33, 84, 86, 94, 108
 ethical considerations related to, 76–7, 241
 privacy issues, 84–6
 bipolar disorder, 49
 brain disease model, of addiction, 5, 186
 breast cancer, 89, 114
 options for prevention of, 114
 British American Tobacco (BAT), 129, 140
 Scientific Research Group (SRC), 142
 bupropion, 157
- caffeine, 232
 California law, 11
 Canavan disease, 17
 Cancer Genetic Markers of Susceptibility (CGEMS) database, 113
 Cancer Genetics Network, 64
 cancer screening exams, 115
 cannabis, 45
 cardiovascular disease, genetic tests for, 115
 catechol-*O*-methyltransferase (COMT), 21
 Center for Indoor Air Research (CIAR), 141
 Centers for Disease Control and Prevention (CDC), 109
 Certificate of Confidentiality, 77, 93–4, 241
 arguments in favor of
 application to genetic research on addiction, 98–9
 Institutional Review Boards (IRBs), requirements by, 99–100
 critiques of
 data protection, need for, 100–1
 false sense of security, 103
 legal implications, 101–2
 protection against compelled disclosure, 102
 documents required to obtain, 104
 history of, 97–8
 instructions for obtaining, 104
 scope of protection under, 98
 strengths and limitations of, 103
 use of
 application process, 104–5
 limitations, real and potential, 103–4
- charitable trust model, 86
 child abuse, 71, 102
 child welfare system, ethical issues related to inclusion of children in custody of, 65
 children, with a substance-abusing parent
 emotional-behavioral difficulty in, 71
 ethical guidelines related to
 biodata banks, 76–7
 community consultation, 62–3
 genotyping, 72–4
 inclusion of children in custody of child welfare system, 65
 institutional review of genetic research, 77
 parental permission, child consent, and child assent, 66–9
 payment of parents and children, 74–6
 phenotyping, 69–72
 recruitment, 63–5
 federal regulation for
 securing child consent and child assent, 67–9
 securing parental permission for empirical research, 66–7
 genetic risk for substance abuse in, 69
 motivation to grant parental permission, for empirical research, 66
 psychosocial development of, 74
 chronic substance abuse, phenotypes associated with risk for, 70
 Clarion Declaration (2008), 150
- Clinical Laboratory Improvement Amendments (CLIA), USA, 73, 115
 cocaine, 45, 185
 Code of Federal Regulations, 9
 coercion, 44
 cognitive behavior therapy, 24
 Collaborative Study on the Genetics of Alcoholism (COGA), 17
 Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence Study (COMBINE), 24
 Common Rule, *see* Federal Policy for the Protection of Human Subjects (Common Rule)
Commonwealth v. Craig Neumyer (2000), 101
 community collaboration, on ethical consideration related to drug abuse, 62–3
 compelled disclosure of information, protection against, 102
 competence, concept of, 43
 Comprehensive Drug Abuse Prevention and Control Act (1970), 97, 98, 101
 compulsion, sense of, 6
 continuum of moral jeopardy, concept of, 131–2
 corporate social responsibility, 139, 146
 corticotropin releasing factor 1 (CRF), 22
 Council for Tobacco Research (CTR), 141, 142
 cystic fibrosis, 160
- database of Genotypes and Phenotypes (dbGaP), 113
 Davenport, Charles, 10
 de-identification, concept of, 89–91
 dementia, 115
 diabetes, 38, 89, 115
Diagnostic and Statistical Manual (DSM-IV), 3
 direct-to-consumer genomic testing, 116
 Disability Adjusted Life Years (DALYs), 16
 discrimination, types of, 176–8
 DNA
 patenting, 118
 sequences, 117

- domestic violence, 93
 dopamine beta hydroxylase (DBH), 21
 dopamine transporter (DAT), 21
 drug abuse, 33
 Drug Abuse Office and Treatment Act (1972), 101
 DTC (direct to consumer)
 genetic tests, premature commercialization of, 162–5
 Duke University Health Systems, 101
- electronic health records (EHRs), 84, 86, 91, 92
 embryonic stem cells, 85
 emotional responses, notion of, 176
 empirical evidence, on genetic attributions and stigma, 186–7
 endogenous opioid system, 20
 endophenotype, 21
 epigenetic mechanisms, and addiction, 218
 Ernest Gallo Clinic and Research Center, 142
 European Research Advisory Board (ERAB), 141
 Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, 158
- Fahrenkopf, Frank, 224
 Federal Policy for the Protection of Human Subjects (Common Rule), 85, 87, 90, 240
 Federation of American Societies for Experimental Biology (FASEB), 148
 fetal alcohol syndrome, 18
 “folk genetic” concepts, 31
 Foundation for Alcohol Research, *see* Alcoholic Beverage Medical Research Foundation (ABMRF)
 funding, for genetic research
 for biomedical and psychosocial research on alcohol, 141
 conflict of interest, approach to minimize effects of
 ethical analysis, 149
 regulatory guidelines, 148–9
 total bans, 149–50
 direct (apparent and unapparent), 140
 implications for
 collegiality among scientists, effects on, 148
 loss of creditability and trust, 147–8
 research bias, in industry-funded research, 146–7
 indirect (third party organizations), 141–2
 industry involvement in, 142
 alcohol industry, 142–3
 gambling industry, 143
 other commercial interests, 143
 tobacco industry, 142
 objectives and strategies for, 144–6
 research ethics associated with, 241–2
 types of, 139–40
- gambling, 84, 125, 126
 funding for genetic research programs related to gambling disorders, 143
 gambling studies, university chair in, 133–4
 gamma-aminobutyric acid (GABA), 19–20
 gene therapy, 85
 genetic essentialism
 concept of, 186
 outcomes related to, 188–9
 Genetic Information
 Nondiscrimination Act (GINA, 2008), 34, 37, 235
 genetic markers, 108
 genetic research, on addiction
 applications of
 individual health, 234
 population health, 233–4
 ethics associated with, 234–42
 funding for, *see* funding, for genetic research
 industry involvement in, 142
 limitations of, 233
 misuses and misunderstandings of, 159
 genetic information by
 industry stakeholders, 162
 premature commercialization of DTC genetic tests, 162–5
 public attitudes and behavior, 159–60
 smoking and alcohol use, 160–2
- potential public health benefits for
 better prevention of addiction, 156
 better treatment of addiction, 156–7
 pharmacogenetic testing for addiction, 157–9
 priorities for, 245
 public health and policy
 implications of, 244–5
 special issues involving children in, 239
 translation and interpretation of
 communication of scientific results, 242–3
 genetic explanations on public understandings, 243–4
 types of, 7–9
 genome sequencing, 94
 genome-wide association studies (GWAS), 17, 35, 113, 156
 genomic databases, 10, 108,
 see also biobanks; Human Genome Project
 and commercialization of
 genomic research, 117–19
 informed consent, fundamental ethical and legal requirements for, 108–11
 returning individualized research results, ethical issues related with, 114–17
 sharing of samples and databases for, 111–14
 genomic medicine, for alcohol dependence
 for personalized treatment of AD, 24–5
 for preventive and predictive screening for susceptibility to AD, 23–4
 genomic research,
 commercialization of, 117–19
 genotyping of children, ethical considerations related to, 72–4
 health records, 86
 glutamate receptor 5 (GluR5) gene, 24
 Goffman, Erving, 174, 182
- habit-forming substances, 2
 Havasupai American Indian tribe, 89, 109

health-care operations, 90	competence, 43	marijuana, 45
Health Fatalism Scale, 200, 206	knowingness, 43–4	Mendelian disorders, 8, 160
health fatalism, due to alcoholism, 206–7	voluntariness, 44	mental illness, 5, 178, 181, 186
health information technology (HIT), 92	fundamental ethical and legal requirements for, 108–11	microarray analysis for genetic research, development of, 8
Health Information Technology for Economic and Clinical Health Act (HITECH Act), USA, 86, 93	history of, 41–2	Milgram's Obedience and Individual Responsibility Study, 41
Health Insurance Portability and Accountability Act (HIPAA), 85, 91, 100, 239, 240	potential vulnerabilities for, 42–3	molecular genomic profiling, 11
health records, privacy issues related to, 86–7	problem and research protocols associated with, 44	monoamine oxidase A (MAOA), 21, 22
Helsinki Declaration (1964), 41, 111	recommendations for, 53–4	<i>Moore v. Regents of University of California</i> (1990), 118
heroin	research ethics associated with, 237–8	moral model, of addiction, 4, 7
addiction, genetic risk of, 38	for research with children, 238	motivational enhancement therapy, 24
replacement therapy, 6	strategies for improving, 46	mu opioid receptor, 20
human behaviors	Institut de Recherches Scientifiques sur les Boissons (IREB), 141	<i>Mutagenesis</i> , 140
for addiction, 215–21	Institute for Research on Pathological Gambling and Related Disorders, 143, 144	naltrexone, 20, 24, 25, 32
individuals and populations in modification of, 221–4	Institute of Medicine's Committee on Clinical Research with Children, 65, 68	National Bioethics Advisory Commission Report, 6
human genetic research on addiction, ethical issues in, 9–10	Institutional Review Boards (IRBs), 34, 42, 75, 85, 103, 105	National Cancer Institute, 64
Human Genome Project, 1, 8, 9, 84, 111, 166, 185	Certificate of Confidentiality, provisions for requirement of, 99–100	National Center for Research on Gambling (NCRG), 141, 143, 145
Human Radiation Experiments, 41	institutional review of genetic research, ethical considerations related to, 77	National Center for Responsible Gaming, 127
Huntington's chorea, 8	intellectual property, 119	National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 42
Huntington's disease, 89, 160	interactional discrimination, mechanism of, 177–8	National Committee on Vital and Health Statistics (NCVHS), 92
Iceland's health-care database, 109	internalized stigma, 177	National Gambling Impact Study, 225
illicit drugs, trade in, 124	International Center for Alcohol Policies (ICAP), 140, 144	National Health and Nutrition Examination Survey (NHANES), 109
individual discrimination, mechanism of, 176–7	<i>International Classification of Mental and Behavioral Disorders-10th revision</i> (ICD-10), 2	National Institute on Alcohol Abuse and Alcoholism (NIAAA), 166
informed consent, for genomic studies	International Scientific Forum on Alcohol Research (ISFAR), 145	National Institute on Drug Abuse (NIDA), 166
autonomy of substance abusers, 45–6	International Society of Addiction Journal Editors (ISAJE), 148	National Institutes of Health (NIH), 93, 94, 97, 104, 241
checklist, 240	intoxication, 6	National Research Act (1974), USA, 42
consent materials, modification of audio-visual technologies, 47–8	knowingness, concept of, 43–4	Nationwide Health Information Network (NWHIN), 86, 91
printed materials, 46–7	Legacy Tobacco Documents, 144	Nazi Eugenic Sterilization Law, 11
consent process, modification of corrected feedback, 48–9	Levy, Neil, 6	Nazi eugenics program, 11
research intermediaries, 49–50	lung cancer, 142	
consent process, strategies for improving, 50	“genetic predisposition” to, 144	
autonomy, 52	genetic susceptibility to, 161	
motivation, 51		
understanding, 50–1		
elements of, 42–3		

250	Index
<p>neurotransmission system, genes that influence, 19</p> <p>dopaminergic system, Taq1A polymorphism of <i>DRD2</i>, 20</p> <p>gamma-aminobutyric acid system (<i>GABRA2</i>), 19–20</p> <p>opioid system, <i>OPRM1</i>, 20–1</p> <p>serotonergic system (<i>5HTTLPR</i>), 21</p> <p>NicoTest, 160, 167</p> <p>nicotine addiction, <i>see</i> nicotine dependence</p> <p>nicotine dependence, 3, 126, 141, 156, 216, 223</p> <p>genetic testing for, 163</p> <p>population screening for, 233</p> <p>nicotine replacement therapy (<i>NRT</i>), 157, 161</p> <p>non-Mendelian disorders, 22, 160</p> <p>not-in-my-backyard (<i>NIMBY</i>) reactions, 178</p> <p>Nuremberg Code (1950), 41</p> <p>Office of Human Research Protections (<i>OHRP</i>), 90</p> <p>Office of Protection from Research Risks (<i>OPRR</i>), 34</p> <p><i>Oncogene</i>, 140</p> <p>ondansetron, 32</p> <p>ontogeny, 215–16</p> <p>opioid drug misuse, patterns of, 3</p> <p><i>OPRM1</i>, 20–1, 32, 38</p> <p>ovarian cancer, 114</p> <p>pathological gambling (<i>PG</i>), 224</p> <p>Pathway Genomics, 38</p> <p>Patriot Act (2001), 104</p> <p>payment of parents and children, ethical considerations related to, 74–6</p> <p>penile cancer, 115</p> <p><i>People v. Newman</i> (1973), 101</p> <p>Personal Genome Project (<i>PGP</i>), 113</p> <p>personalized genomic medicine, 17</p> <p>pharmacogenetic testing</p> <p>for improving AD treatment efficacy, 24–5</p> <p>for naltrexone response, 25</p> <p>phenotyping of children, ethical considerations related to, 69–72</p> <p>health records, 86</p> <p>phylogeny, 216</p> <p>pleiotropy, 158</p>	<p>population-based genetic screening, 37</p> <p>potency products, 126</p> <p>prescription medications, abuse of, 88</p> <p>President's Council of Advisors on Science and Technology, 93</p> <p>printed consent materials, modification of, 46–7</p> <p>privacy issues</p> <p>raised by different research methods</p> <p>biobanks, 84–6</p> <p>health records, 86–7</p> <p>interventional research with human subjects, 87–8</p> <p>in research on alcohol dependence and other addictions</p> <p>family harms, 88–9</p> <p>group harms, 89</p> <p>individual harms, 88</p> <p>strategy for protection of</p> <p>Certificate of Confidentiality, 93–4</p> <p>de-identification, 89–91</p> <p>sensitive health information, sequestration of, 91–3</p> <p>Privacy Rule, <i>see</i> Standards for the Protection of Individually Identifiable Information (Privacy Rule)</p> <p>product design research, funded by tobacco industry, 134–5</p> <p>pseudo-Mendelian disorders, 17</p> <p>psychiatric disorders, 35, 36</p> <p>psychoactive substances, 1</p> <p>public health, 90</p> <p>Public Health Services Act (1988), 93, 97</p> <p>public intoxication, 88</p> <p>quasi-Mendelian disorder, 17</p> <p>recreational drugs, 117</p> <p><i>Regulations for the Protection of Human Subjects of Biomedical and Behavioral Research</i> (2009), 62</p> <p>research bias, in industry-funded genetic research, 146–7</p> <p>research ethics</p> <p>for informed consent, 237–8</p> <p>for research with children, 238</p> <p>problem of reuse in future research, 238–9</p> <p>for protecting privacy and confidentiality, 240–1</p> <p>for recruitment, 236–7</p> <p>of children, 237</p> <p>related to</p> <p>biobanks and the storage of data, 241</p> <p>funding sources, 241–2</p> <p>risks, types of, 234</p> <p>relatives and groups, 236</p> <p>subjects, 234–5</p> <p>for sharing information about research findings, 239–40</p> <p>research intermediary, 49–50</p> <p>RESPECT Code of Practice, 148</p> <p>“risk gene”, 8</p> <p>Rothstein, Mark, 97</p> <p>schizophrenia, 34, 176, 181, 184</p> <p>sensitive health information, sequestration of, 91–3</p> <p>serotonin, 21</p> <p>serotonin transporter gene (<i>SLC6A4</i>), 21</p> <p>sexual abuse, 111</p> <p>single nucleotide polymorphism (<i>SNP</i>), 24, 112, 156, 157</p> <p>Smith, Richard, 129</p> <p>smoking cessation</p> <p>pharmacogenetics of, 25</p> <p>treatment of, 158</p> <p>social distance, 187</p> <p>Standards for the Protection of Individually Identifiable Information (Privacy Rule), 85, 86, 90</p> <p><i>State v. Bradley</i> (2006), 101, 104</p> <p>status loss, concept of, 176</p> <p>sterilization, of mentally deficient people, 10</p> <p>stigma</p> <p>addiction, associated with, 181–5</p> <p>attribution theory of, 185–6</p> <p>characteristics and dimensions of, 178–9</p> <p>conceptual model of, 174–8</p> <p>definition of, 174–5</p> <p>dependence on power, 178</p> <p>differences with negative attributes, 175</p> <p>and discrimination, 176–8</p> <p>distinguishing and labeling differences, 175</p> <p>emotional responses, 176</p> <p>and emotions of fear, danger, and unpredictability, 188</p>

empirical evidence on, 186–7	stress response system, genetic variations in, 21	funding for genetic research programs related to tobacco addiction, 142
for enforcement of social norms, 179–80	structural discrimination, mechanism of, 178	tolerance, 3
exploitation and domination, concept of, 179	substance-use disorders, 31, 32, 61, <i>see also</i> addiction	Tuskegee Syphilis Study, 41, 42
functions of, 179	autonomy of substance abusers participating in research, 45–6	US Master Settlement Agreement, 144
general measures for prejudice and bias, 188	effect on understanding, attention and recall aspects of patients, 45	voluntariness, concept of, 44
geneticization and, 185–7	implications related to, 35–8	Watson, James, 186
implications for addictions, 189–90	public beliefs in genetic causes of, 185	Wechsler Adult Intelligence Scale (WAIS), 44
as a means for avoidance of disease, 180–1	risks related to research conduct in patients with, 32–5	withdrawal syndrome, 3, 6, 16
outcomes related to attribution theory, 188	stigma associated with, 33	World Health Organization (WHO), 1, 6, 125
genetic essentialism, 188–9	Taq1A polymorphism, of <i>DRD2</i> , 20	World Medical Association, 41
separation of “us” from “them”, notion of, 175–6	“tissue trustee” model, 85	Yaffe, Gideon, 6
and social distance, 187	tobacco, 1, 125, 126, 134, 141	youth alcohol consumption, public health research on, 132–3
and status loss, 176		
<i>Stigma: Notes on the Management of Spoiled Identity</i> (1963), 174		